Published in Nat Commun on January 01, 2013
Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A. J Biol Chem (2014) 0.92
Deleted in liver cancer-1 (DLC1): an emerging metastasis suppressor gene. Mol Diagn Ther (2014) 0.79
AMPK and PKA interaction in the regulation of survival of liver cancer cells subjected to glucose starvation. Oncotarget (2016) 0.78
Resveratrol inhibits age-dependent spontaneous tumorigenesis by SIRT1-mediated post-translational modulations in the annual fish Nothobranchius guentheri. Oncotarget (2017) 0.75
Rho GTPases in cancer cell biology. FEBS Lett (2008) 4.47
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res (1998) 2.59
Serine phosphorylation negatively regulates RhoA in vivo. J Biol Chem (2003) 2.28
Mutations in regulatory subunit type 1A of cyclic adenosine 5'-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab (2009) 2.23
Regulation of actin-based cell migration by cAMP/PKA. Biochim Biophys Acta (2004) 2.15
The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J Cell Biol (2006) 2.10
Rho GTPases in transformation and metastasis. Adv Cancer Res (2002) 2.07
The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res (2005) 1.94
Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci U S A (2007) 1.87
Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res (2003) 1.87
Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res (2006) 1.76
Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res (2005) 1.73
DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol Carcinog (2008) 1.67
Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver. Int J Biochem Cell Biol (2007) 1.64
Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex. EMBO J (2004) 1.58
Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proc Natl Acad Sci U S A (2004) 1.56
Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. Gastroenterology (2010) 1.52
Protein kinase A governs a RhoA-RhoGDI protrusion-retraction pacemaker in migrating cells. Nat Cell Biol (2011) 1.51
Release of cAMP gating by the alpha6beta4 integrin stimulates lamellae formation and the chemotactic migration of invasive carcinoma cells. J Cell Biol (1998) 1.50
Cyclic AMP inhibition of proliferation of hepatocellular carcinoma cells is mediated by Akt. Cancer Biol Ther (2005) 1.46
Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci U S A (2005) 1.40
Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev (2009) 1.36
DLC1: a significant GAP in the cancer genome. Genes Dev (2008) 1.36
Plexins are GTPase-activating proteins for Rap and are activated by induced dimerization. Sci Signal (2012) 1.23
DLC1 interacts with 14-3-3 proteins to inhibit RhoGAP activity and block nucleocytoplasmic shuttling. J Cell Sci (2008) 1.17
Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation. Proc Natl Acad Sci U S A (2012) 1.16
Deleted in liver cancer 3 (DLC-3), a novel Rho GTPase-activating protein, is downregulated in cancer and inhibits tumor cell growth. Oncogene (2007) 1.12
p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene (2009) 1.12
Mutations in the focal adhesion targeting region of deleted in liver cancer-1 attenuate their expression and function. Cancer Res (2008) 1.09
Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function. PLoS One (2009) 1.05
Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proc Natl Acad Sci U S A (2011) 1.00
The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. J Cell Sci (2009) 0.98
srGAP2 arginine methylation regulates cell migration and cell spreading through promoting dimerization. J Biol Chem (2010) 0.97
High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. Oncogene (2007) 0.97
Solution structures, dynamics, and lipid-binding of the sterile alpha-motif domain of the deleted in liver cancer 2. Proteins (2007) 0.96
DLC1 negatively regulates angiogenesis in a paracrine fashion. Cancer Res (2010) 0.95
DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain. Mol Biol Cell (2009) 0.94
DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism. Cancer Res (2011) 0.93
cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity. Cell Signal (2011) 0.92
Different expression of protein kinase A (PKA) regulatory subunits in cortisol-secreting adrenocortical tumors: relationship with cell proliferation. Exp Cell Res (2007) 0.91
Deleted in liver cancer protein family in human malignancies (Review). Oncol Lett (2011) 0.89
cAMP response element-binding protein is expressed at high levels in human ovarian adenocarcinoma and regulates ovarian tumor cell proliferation. Int J Gynecol Cancer (2008) 0.88
Cyclic AMP induces inhibition of cyclin A expression and growth arrest in human hepatoma cells. Biochim Biophys Acta (1999) 0.85
Cell migration: PKA and RhoA set the pace. Curr Biol (2011) 0.84
The tumor suppressor protein DLC1 is regulated by PKD-mediated GAP domain phosphorylation. Exp Cell Res (2010) 0.81
Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo. PLoS One (2011) 0.76
Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology (2007) 5.75
Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science (2002) 2.45
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl (2005) 2.43
Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med (2003) 2.33
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. Proc Natl Acad Sci U S A (2011) 2.17
Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. J Hepatol (2010) 1.97
MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology (2010) 1.88
The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. Gastroenterology (2010) 1.85
HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology (2004) 1.83
Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest (2007) 1.79
Abdominal drainage after hepatic resection is contraindicated in patients with chronic liver diseases. Ann Surg (2004) 1.79
Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res (2006) 1.76
Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. J Clin Oncol (2002) 1.75
A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A (2005) 1.74
Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res (2005) 1.73
Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology (2010) 1.66
Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int (2011) 1.60
Swi/Snf chromatin remodeling/tumor suppressor complex establishes nucleosome occupancy at target promoters. Proc Natl Acad Sci U S A (2013) 1.60
A haplotype map of genomic variations and genome-wide association studies of agronomic traits in foxtail millet (Setaria italica). Nat Genet (2013) 1.58
5-(Methoxy-carbon-yl)thio-phene-2-carboxylic acid. Acta Crystallogr Sect E Struct Rep Online (2009) 1.57
Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology (2012) 1.55
Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos (2011) 1.54
Smoke carcinogens cause bone loss through the aryl hydrocarbon receptor and induction of Cyp1 enzymes. Proc Natl Acad Sci U S A (2013) 1.54
Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery (2005) 1.54
AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells. Cancer Res (2012) 1.52
Akt phosphorylation of deleted in liver cancer 1 abrogates its suppression of liver cancer tumorigenesis and metastasis. Gastroenterology (2010) 1.52
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol (2007) 1.51
Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor α1. Biochem J (2013) 1.45
Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg (2005) 1.44
Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. Liver Transpl (2003) 1.44
Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci U S A (2005) 1.40
Nitric oxide synthase inhibition abolishes exercise-mediated protection against isoproterenol-induced cardiac hypertrophy in female mice. Cardiology (2015) 1.38
Synthesis and antifungal activities of 5-(3,4,5-trimethoxyphenyl)-2-sulfonyl-1,3,4-thiadiazole and 5-(3,4,5-trimethoxyphenyl)-2-sulfonyl-1,3,4-oxadiazole derivatives. Bioorg Med Chem (2007) 1.35
HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing. Oncogene (2005) 1.34
Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology (2009) 1.34
Prognosis after hepatic resection for stage IVA hepatocellular carcinoma: a need for reclassification. Ann Surg (2003) 1.27
Phacoemulsification induced transient swelling of corneal Descemet's Endothelium Complex imaged with ultra-high resolution optical coherence tomography. PLoS One (2013) 1.26
Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos (2004) 1.24
Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer (2003) 1.24
Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One (2012) 1.22
Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells. Breast Cancer Res (2014) 1.19
Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology (2007) 1.18
Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proc Natl Acad Sci U S A (2013) 1.17
Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg (2003) 1.17
P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res (2007) 1.17
In situ observation of graphene sublimation and multi-layer edge reconstructions. Proc Natl Acad Sci U S A (2009) 1.15
A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer (2005) 1.14
Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology (2012) 1.13
Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. Cancer Chemother Pharmacol (2002) 1.11
Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. PLoS One (2011) 1.11
Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg (2011) 1.10
Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer. Breast Cancer Res (2003) 1.10
Vertical and horizontal thickness profiles of the corneal epithelium and Bowman's layer after orthokeratology. Invest Ophthalmol Vis Sci (2013) 1.10
Clinical implications for nestin protein expression in breast cancer. Cancer Sci (2009) 1.10
Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol (2003) 1.10
Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology (2014) 1.09
Deleted in liver cancer 1 (DLC1) negatively regulates Rho/ROCK/MLC pathway in hepatocellular carcinoma. PLoS One (2008) 1.08
Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. Hepatology (2014) 1.08
2-(Tritylsulfan-yl)ethyl 2-iodo-benzoate. Acta Crystallogr Sect E Struct Rep Online (2011) 1.08
Assessment of genetic diversity in broomcorn millet (Panicum miliaceum L.) using SSR markers. J Genet Genomics (2009) 1.07
Girdin protein: a new potential distant metastasis predictor of breast cancer. Med Oncol (2011) 1.07
Ultrahigh thermoelectric performance by electron and phonon critical scattering in Cu2 Se1-x Ix. Adv Mater (2013) 1.07
BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Res (2012) 1.07
Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. Hepatology (2012) 1.06
Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function. PLoS One (2009) 1.05
Impact of pH on plasma protein binding in equilibrium dialysis. Mol Pharm (2008) 1.05
Prognostic role of lymphatic vessel invasion in early gastric cancer: a retrospective study of 188 cases. Surg Oncol (2008) 1.04
Liver transplantation for combined hepatocellular cholangiocarcinoma. Asian J Surg (2007) 1.04
Buckyballs meet viral nanoparticles: candidates for biomedicine. J Am Chem Soc (2009) 1.04
Generation and selection of novel fully human monoclonal antibodies that neutralize Dickkopf-1 (DKK1) inhibitory function in vitro and increase bone mass in vivo. J Biol Chem (2010) 1.04
Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood (2005) 1.04
Genetic diversity and population structure of Chinese foxtail millet [Setaria italica (L.) Beauv.] landraces. G3 (Bethesda) (2012) 1.04
Clinical implications of metastatic lymph node ratio in gastric cancer. BMC Cancer (2007) 1.03
Lymph node ratio is an independent prognostic factor in gastric cancer after curative resection (R0) regardless of the examined number of lymph nodes. Am J Clin Oncol (2013) 1.03
Caveolin-1 overexpression is associated with hepatocellular carcinoma tumourigenesis and metastasis. J Pathol (2012) 1.03
Overexpression of a novel activator of PAK4, the CDK5 kinase-associated protein CDK5RAP3, promotes hepatocellular carcinoma metastasis. Cancer Res (2011) 1.02
High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol (2004) 1.01
Evaluation of nuclear factor-kappaB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res (2004) 1.01
Notch1-Snail1-E-cadherin pathway in metastatic hepatocellular carcinoma. Int J Cancer (2011) 1.01
High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. Cancer (2002) 1.01
Massive sorghum collection genotyped with SSR markers to enhance use of global genetic resources. PLoS One (2013) 1.01
Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. Hepatology (2006) 1.00
Regulation of hepatocarcinogenesis by microRNAs. Front Biosci (Elite Ed) (2013) 1.00
Transcriptome profiling and digital gene expression by deep-sequencing in normal/regenerative tissues of planarian Dugesia japonica. Genomics (2011) 1.00
Mitochondrial targeting of growth suppressor protein DLC2 through the START domain. FEBS Lett (2005) 1.00
Fiber bragg gratings made with a phase mask and 800-nm femtosecond radiation. Opt Lett (2003) 1.00
Mohawk promotes the tenogenesis of mesenchymal stem cells through activation of the TGFβ signaling pathway. Stem Cells (2015) 1.00
Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. PLoS One (2011) 0.99
Ultraviolet radiation stimulates expression of Snail family transcription factors in keratinocytes. Mol Carcinog (2007) 0.99
Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B. Am J Gastroenterol (2004) 0.99
The role of the slug transcription factor in cell migration during corneal re-epithelialization in the dog. Exp Eye Res (2006) 0.98